Works by Alam, John J.

Results: 11

Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis.

Published in:

Annals of Neurology, 1998, v. 43, n. 1, p. 79, doi. 10.1002/ana.410430114

By:

Simon, Jack H.;
Jacobs, Lawrence D.;
Campion, Marilyn;
Wende, Karl;
Simonian, Nancy;
Cookfair, Diane L.;
Rudick, Richard A.;
Herndon, Robert M.;
Richert, John R.;
Salazar, Andres M.;
Alam, John J.;
Fischer, Jill S.;
Goodkin, Donald E.;
Granger, Carl V.;
Lajaunie, Michelle;
Martens-Davidson, Anna L.;
Meyer, Maryjoel;
Sheeder, Jeanelle;
Choi, Kim;
Scherzinger, Ann L.

Publication type:

Article

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis.

Published in:

Annals of Neurology, 1996, v. 39, n. 3, p. 285, doi. 10.1002/ana.410390304

By:

Jacobs, Lawrence D.;
Cookfair, Diane L.;
Rudick, Richard A.;
Herndon, Robert M.;
Richert, John R.;
Salazar, Andres M.;
Fischer, Jill S.;
Goodkin, Donald E.;
Granger, Carl V.;
Simon, Jack H.;
Alam, John J.;
Bartoszak, David M.;
Bourdette, Dennis N.;
Braiman, Jonathan;
Brownscheidle, Carol M.;
Coats, Michael E.;
Cohan, Stanley L.;
Dougherty, David S.;
Kinkel, Revere P.;
Mass, Michele K.

Publication type:

Article

A Viral Dynamic Model for Treatment Regimens with Direct-acting Antivirals for Chronic Hepatitis C Infection.

Published in:

PLoS Computational Biology, 2012, v. 8, n. 1, p. 1, doi. 10.1371/journal.pcbi.1002339

By:

Adiwijaya, Bambang S.;
Kieffer, Tara L.;
Henshaw, Joshua;
Eisenhauer, Karen;
Kimko, Holly;
Alam, John J.;
Kauffman, Robert S.;
Garg, Varun

Publication type:

Article

Correction: Drug development targeting degeneration of the basal forebrain cholinergic system: its time has come.

Published in:

2023

By:

Alam, John J.;
Nixon, Ralph A.

Publication type:

Correction Notice

Drug development targeting degeneration of the basal forebrain cholinergic system: its time has come.

Published in:

Molecular Neurodegeneration, 2023, v. 18, n. 1, p. 1, doi. 10.1186/s13024-023-00663-y

By:

Alam, John J.;
Nixon, Ralph A.

Publication type:

Article

A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease.

Published in:

Alzheimer's Research & Therapy, 2021, v. 13, n. 1, p. 1, doi. 10.1186/s13195-021-00843-2

By:

Prins, Niels D.;
Harrison, John E.;
Chu, Hui-May;
Blackburn, Kelly;
Alam, John J.;
Scheltens, Philip;
for the REVERSE-SD Study Investigators;
Arnold;
Coskinas;
Gonzales;
Joseph;
Khan;
McConnehey;
Paricio;
Taylor;
Rowell, Zarate;
Groom;
Summers;
White;
Thein

Publication type:

Article

Impaired Bioavailability of Interferon Beta-1a when Administered Intramuscularly by Needle-Free Injection.

Published in:

Drug Delivery, 1998, v. 5, n. 4, p. 275, doi. 10.3109/10717549809065758

By:

Rogge, Mark C.;
Charenkavanich, Supoat;
Dibiase, Mary;
Jones, Wendy;
Knox, Steven J.;
Alam, John J.

Publication type:

Article

P38α MAPK Signaling—A Robust Therapeutic Target for Rab5-Mediated Neurodegenerative Disease.

Published in:

International Journal of Molecular Sciences, 2020, v. 21, n. 15, p. 5485, doi. 10.3390/ijms21155485

By:

Germann, Ursula A.;
Alam, John J.

Publication type:

Article

Continuous administration of a p38α inhibitor during the subacute phase after transient ischemia-induced stroke in the rat promotes dose-dependent functional recovery accompanied by increase in brain BDNF protein level.

Published in:

PLoS ONE, 2020, v. 15, n. 12, p. 1, doi. 10.1371/journal.pone.0233073

By:

Alam, John J.;
Krakovsky, Michael;
Germann, Ursula;
Levy, Aharon

Publication type:

Article

Neflamapimod treatment reduces plasma glial fibriallary acidic protein levels in patients with pure dementia with Lewy bodies (DLB).

Published in:

Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2024, v. 20, n. S6, p. 1, doi. 10.1002/alz.091713

By:

Alam, John J;
Koel‐Simmerlink, Marleen JA;
Conway, Jennifer;
Verberk, Inge M.W.;
Teunissen, Charlotte

Publication type:

Article

Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration.

Published in:

Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-32944-3

By:

Jiang, Ying;
Alam, John J.;
Gomperts, Stephen N.;
Maruff, Paul;
Lemstra, Afina W.;
Germann, Ursula A.;
Stavrides, Philip H.;
Darji, Sandipkumar;
Malampati, Sandeep;
Peddy, James;
Bleiwas, Cynthia;
Pawlik, Monika;
Pensalfini, Anna;
Yang, Dun-Sheng;
Subbanna, Shivakumar;
Basavarajappa, Balapal S.;
Smiley, John F.;
Gardner, Amanda;
Blackburn, Kelly;
Chu, Hui-May

Publication type:

Article